New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

A panelist discusses how a man aged 82 years with good performance status presented with unexplained weight loss and abdominal pain, leading to a diagnosis of metastatic pancreatic adenocarcinoma with ...

Berlin: Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, have announced that they have entered into an ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Verastem ( ($VSTM) ) just unveiled an announcement. On August 13, 2025, Verastem announced updated safety and efficacy data from the VS-7375 Phase ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Verastem Oncology has announced the dosing of the first patient with GFH375/VS-7375, a potent and selective oral KRAS G12D (ON/OFF) inhibitor, as part of a Phase I/II clinical trial in China.

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...